NasdaqCM - Delayed Quote USD

NeuroMetrix, Inc. (NURO)

4.3300 +0.7000 (+19.28%)
At close: 4:00 PM EDT
4.4300 +0.10 (+2.31%)
After hours: 7:35 PM EDT
Loading Chart for NURO
DELL
  • Previous Close 3.6300
  • Open 3.9200
  • Bid 4.1600 x 1000
  • Ask 4.3700 x 200
  • Day's Range 3.9200 - 4.4465
  • 52 Week Range 2.7000 - 11.8400
  • Volume 253,781
  • Avg. Volume 45,082
  • Market Cap (intraday) 8.602M
  • Beta (5Y Monthly) 2.32
  • PE Ratio (TTM) --
  • EPS (TTM) -6.2700
  • Earnings Date May 1, 2024 - May 6, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date Mar 28, 2007
  • 1y Target Est --

NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.

www.neurometrix.com

26

Full Time Employees

December 31

Fiscal Year Ends

Recent News: NURO

Performance Overview: NURO

Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

NURO
20.28%
S&P 500
4.14%

1-Year Return

NURO
62.15%
S&P 500
19.55%

3-Year Return

NURO
82.87%
S&P 500
18.68%

5-Year Return

NURO
94.36%
S&P 500
70.99%

Compare To: NURO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NURO

Valuation Measures

As of 4/19/2024
  • Market Cap

    7.25M

  • Enterprise Value

    -10.51M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.64

  • Price/Book (mrq)

    0.36

  • Enterprise Value/Revenue

    -1.78

  • Enterprise Value/EBITDA

    1.48

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -110.64%

  • Return on Assets (ttm)

    -19.39%

  • Return on Equity (ttm)

    -30.06%

  • Revenue (ttm)

    5.9M

  • Net Income Avi to Common (ttm)

    -6.53M

  • Diluted EPS (ttm)

    -6.2700

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    18M

  • Total Debt/Equity (mrq)

    1.20%

  • Levered Free Cash Flow (ttm)

    -3.71M

Research Analysis: NURO

Fair Value

Overvalued
% Return
4.3300 Current
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS
 

People Also Watch